NASDAQ:OMCL

Omnicell - OMCL Stock Forecast, Price & News

$87.03

-0.81 (-0.92%)

(As of 09/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $86.91
▼
$90.68
50-Day Range: $84.23
▼
$112.23
52-Week Range: $83.78
▼
$187.29

Volume: 372,865 shs
Average Volume: 405,041 shs
Market Capitalization: $3.85 billion

P/E Ratio: 69.07
Dividend Yield: N/A
Price Target: $149.88

Omnicell MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.88 Rating Score
Upside/Downside: 72.2% Upside
$149.88 Price Target
Short Interest: Bearish
6.75% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.58
Based on 12 Articles This Week
Insider Trading: Selling Shares
$4.29 M Sold Last Quarter
Proj. Earnings Growth: 27.31%
From $2.60 to $3.31 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.77 out of 5 stars

Medical Sector

71st out of 1,095 stocks

Electronic Computers Industry

4th out of 5 stocks

4.4

Analyst's Opinion

Consensus Rating
Omnicell has received a consensus rating of Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $149.88, Omnicell has a forecasted upside of 72.2% from its current price of $87.03.
Amount of Analyst Coverage
Omnicell has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
6.75% of the outstanding shares of Omnicell have been sold short.
Short Interest Ratio / Days to Cover
Omnicell has a short interest ratio ("days to cover") of 5.2.
Change versus previous month
Short interest in Omnicell has recently decreased by 0.99%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Omnicell does not currently pay a dividend.
Dividend Growth
Omnicell does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for OMCL.

2.5

News and Social Media Coverage

News Sentiment
Omnicell has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.83 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for Omnicell this week, compared to 5 articles on an average week.
Search Interest
Only 2 people have searched for OMCL on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.
MarketBeat Follows
3 people have added Omnicell to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Omnicell insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,287,245.00 in company stock.
Percentage Held by Insiders
Only 2.76% of the stock of Omnicell is held by insiders.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Omnicell are expected to grow by 27.31% in the coming year, from $2.60 to $3.31 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Omnicell is 69.07, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 121.98.
Price to Earnings Ratio vs. Sector
The P/E ratio of Omnicell is 69.07, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 113.14.
Price to Earnings Growth Ratio
Omnicell has a PEG Ratio of 2.20. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Omnicell has a P/B Ratio of 3.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Omnicell (NASDAQ:OMCL) Stock

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.

Receive OMCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Omnicell and its competitors with MarketBeat's FREE daily newsletter.

OMCL Stock News Headlines

October 1, 2022 | americanbankingnews.com

Omnicell, Inc. (NASDAQ:OMCL) Receives $149.88 Consensus Price Target from Analysts

September 30, 2022 | finance.yahoo.com

Pharmacy Inventory Management Software Solutions and Cabinets Global Market Report 2022 - Yahoo Finance

September 29, 2022 | finance.yahoo.com

Medication Management System Global Market Report 2022 - Yahoo Finance

September 28, 2022 | finance.yahoo.com

The Group Savings Organization Expands Board of Advisors with Three Nationally Renowned Healthcare Business Leaders - Yahoo Finance

September 28, 2022 | businesswire.com

The Group Savings Organization Expands Board of Advisors with Three Nationally Renowned Healthcare Business Leaders - Business Wire

September 25, 2022 | americanbankingnews.com

Q2 2023 EPS Estimates for Omnicell, Inc. (NASDAQ:OMCL) Increased by Analyst

September 25, 2022 | americanbankingnews.com

Omnicell, Inc. (NASDAQ:OMCL) Forecasted to Earn Q4 2022 Earnings of $0.78 Per Share

September 24, 2022 | americanbankingnews.com

Omnicell (NASDAQ:OMCL) Price Target Cut to $157.00 by Analysts at Benchmark

September 23, 2022 | uk.investing.com

Spero Therapeutics To Rally Around 240%? Plus This Analyst Slashes PT On Salesforce By Benzinga - Investing.com UK

September 23, 2022 | streetinsider.com

National Association of Specialty Pharmacy (NASP) Announces Industry and Poster Awards at the 2022 Annual Meeting & Expo - StreetInsider.com

September 23, 2022 | finance.yahoo.com

National Association of Specialty Pharmacy (NASP) Announces Industry and Poster Awards at the 2022 Annual Meeting & Expo - Yahoo Finance

September 23, 2022 | americanbankingnews.com

Omnicell (NASDAQ:OMCL) Price Target Cut to $160.00 by Analysts at BTIG Research

September 23, 2022 | americanbankingnews.com

Omnicell (NASDAQ:OMCL) PT Lowered to $145.00

September 22, 2022 | businesswire.com

Advantage Healthcare Partners with Spencer Health Solutions to Improve Outcomes for Behavioral Health Patients Enrolled in Pharma Support Programs - Business Wire

September 21, 2022 | uk.investing.com

Morgan Stanley To Rally Over 10%? Here Are 5 Other Price Target Changes For Wednesday By Benzinga - Investing.com UK

September 20, 2022 | businesswire.com

Omnicell Highlights Differentiated Strategy and Unique Business Model at 2022 Investor Day - Business Wire

September 10, 2022 | benzinga.com

Automatic Pill Dispenser Machine Market Report 2022: Integration of AI Presents Lucrative Opportunities - Benzinga

September 9, 2022 | benzinga.com

Omnicell (NASDAQ:OMCL) – What 4 Analyst Ratings Have To Say About Omnicell - Benzinga

September 8, 2022 | finance.yahoo.com

Should Weakness in Omnicell, Inc.'s (NASDAQ:OMCL) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

September 6, 2022 | globenewswire.com

Global Medical Carts Market to Reach Valuation of $4,003.25 - GlobeNewswire

September 2, 2022 | benzinga.com

Omnicell (OMCL) – Omnicell to Present at the 2022 Wells Fargo Healthcare Conference - Benzinga

August 30, 2022 | finance.yahoo.com

The Global Preventive Healthcare Market grew USD 5,512.89 billion by 2027, at a CAGR of 8.32%. - Yahoo Finance

August 30, 2022 | globenewswire.com

The Global Preventive Healthcare Market grew USD 5,512.89 - GlobeNewswire

August 25, 2022 | businesswire.com

Omnicell to Host Investor Day on September 20, 2022 - Business Wire

August 24, 2022 | nasdaq.com

Omnicell, Inc.'s (NASDAQ:OMCL) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong? - Nasdaq

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive OMCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Omnicell and its competitors with MarketBeat's FREE daily newsletter.

OMCL Company Calendar

Last Earnings: 8/04/2022
Today: 10/02/2022
Next Earnings (Estimated): 11/01/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Electronic computers
Sub-Industry: Health Care Technology
Sector: Medical
Current Symbol: NASDAQ:OMCL
CUSIP: 68213N10
CIK: 926326
Web: www.omnicell.com
Phone: (650) 251-6100
Fax: 847-596-3402
Employees: 3,800
Year Founded: 1992

Price Target and Rating

Average Stock Price Forecast: $149.88
High Stock Price Forecast: $205.00
Low Stock Price Forecast: $120.00
Forecasted Upside/Downside: +72.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.88
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): $1.26
Trailing P/E Ratio: 69.07
Forward P/E Ratio: 33.47
P/E Growth: 2.2
Net Income: $77.85 million
Net Margins: 4.82%
Pretax Margin: 3.65%
Return on Equity: 10.37%
Return on Assets: 5.43%

Debt

Debt-to-Equity Ratio: 0.52
Current Ratio: 2.11
Quick Ratio: 1.71

Sales & Book Value

Annual Sales: $1.13 billion
Price / Sales: 3.41
Cash Flow: $5.30 per share
Price / Cash Flow: 16.43
Book Value: $26.09 per share
Price / Book: 3.34

Miscellaneous

Outstanding Shares: 44,290,000
Free Float: 43,067,000
Market Cap: $3.85 billion
Optionable: Optionable
Beta: 1.06

Social Links

Key Executives

Mr. Randall A. Lipps (Age 65)
Founder, Exec. Chairman, Pres & CEO
Comp: $2.44M

Mr. Peter J. Kuipers (Age 50)
Exec. VP & CFO
Comp: $1.18M

Ms. Christine Mellon (Age 59)
Exec. VP, Chief Admin. & People Officer
Comp: $768.28k

Mr. Scott Peter Seidelmann (Age 46)
Exec. VP & Chief Commercial Officer
Comp: $1.17M

Mr. Joseph Brian Spears (Age 62)
Sr. VP, Chief Accounting Officer & Corp. Controller

Mr. Giri Chodavarapu
Sr. VP & Chief Information Officer

Ms. Kathleen Nemeth
Sr. VP of Investor Relations

Mr. Corey J. Manley
Sr. VP & Chief Legal Officer

Ms. Roxanne Turner
Sr. VP of Corp. Responsibility and Chief Compliance & Privacy Officer

Mr. Jorge R. Taborga (Age 63)
Exec. VP of Engineering & Integration Management Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OMCL Stock - Frequently Asked Questions

Should I buy or sell Omnicell stock right now?: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OMCL shares.
View OMCL analyst ratings or view top-rated stocks.
What is Omnicell's stock price forecast for 2022?: 8 analysts have issued 12-month price targets for Omnicell's shares. Their OMCL share price forecasts range from $120.00 to $205.00. On average, they expect the company's stock price to reach $149.88 in the next twelve months. This suggests a possible upside of 72.2% from the stock's current price.
View analysts price targets for OMCL or view top-rated stocks among Wall Street analysts.
How have OMCL shares performed in 2022?: Omnicell's stock was trading at $180.44 at the beginning of the year. Since then, OMCL shares have decreased by 51.8% and is now trading at $87.03.
View the best growth stocks for 2022 here.
When is Omnicell's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our OMCL earnings forecast.
How were Omnicell's earnings last quarter?: Omnicell, Inc. (NASDAQ:OMCL) released its earnings results on Thursday, August, 4th. The company reported $0.84 earnings per share for the quarter, missing analysts' consensus estimates of $0.85 by $0.01. The firm earned $331.39 million during the quarter, compared to analysts' expectations of $339.45 million. Omnicell had a trailing twelve-month return on equity of 10.37% and a net margin of 4.82%. The business's revenue was up 21.5% on a year-over-year basis. During the same period last year, the company earned $0.71 EPS.
What guidance has Omnicell issued on next quarter's earnings?: Omnicell issued an update on its FY 2025 earnings guidance on Tuesday, September, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.90 billion-$2.00 billion.

What is Randall A. Lipps' approval rating as Omnicell's CEO?: 150 employees have rated Omnicell Chief Executive Officer Randall A. Lipps on Glassdoor.com. Randall A. Lipps has an approval rating of 68% among the company's employees.
What other stocks do shareholders of Omnicell own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Omnicell investors own include AT&T (T), AbbVie (ABBV), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Adobe (ADBE), Micron Technology (MU), NVIDIA (NVDA), Applied Materials (AMAT), Alibaba Group (BABA) and Intel (INTC).
What is Omnicell's stock symbol?: Omnicell trades on the NASDAQ under the ticker symbol "OMCL."
How do I buy shares of Omnicell?: Shares of OMCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Omnicell's stock price today?: One share of OMCL stock can currently be purchased for approximately $87.03.
How much money does Omnicell make?: Omnicell (NASDAQ:OMCL) has a market capitalization of $3.85 billion and generates $1.13 billion in revenue each year. The company earns $77.85 million in net income (profit) each year or $1.26 on an earnings per share basis.
How many employees does Omnicell have?: The company employs 3,800 workers across the globe.
Does Omnicell have any subsidiaries?: The following companies are subsidiares of Omnicell: 340B Link Business, Aesynt, Aesynt B.V., Aesynt Holding B.V., Aesynt Holding Cooperatief U.A., Aesynt Pty Ltd., Aesynt S.r.l, Aruba S.r.l, Ateb Inc. , Health Robotics S.r.l., InPharmics, MTS Medication Technologies Inc., MTS Packing Systems Inc., Mach 4 Automatisierungs Technik GmbH, MedPak Holdings Inc., Omnicell (Beijing) Technology Co. Ltd., Omnicell GmbH, Omnicell International LLC, Omnicell Ltd., and Omnicell SAS.
Read More
How can I contact Omnicell?: Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The official website for the company is www.omnicell.com. The company can be reached via phone at (650) 251-6100, via email at ir@omnicell.com, or via fax at 847-596-3402.

This page (NASDAQ:OMCL) was last updated on 10/2/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Omnicell - OMCL Stock Forecast, Price & News

Omnicell MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows